Results from the company’s investigational study suggested that Orencia reduced flare-ups of the disease in children who were not helped by other anti-rheumatic drugs such as methotrexate or tumor necrosis factor antagonists.
The ongoing study is designed to assess the efficacy, safety and tolerability of Orencia in patients ranging from six years to 17 years old.